AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
15 mai 2023 08h45 HE
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
13 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillionThe role of activated microglia is well-established...
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
12 avr. 2023 08h35 HE
|
AIM ImmunoTech Inc.
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM...
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
04 avr. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
03 avr. 2023 06h30 HE
|
AIM ImmunoTech Inc.
– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones –...
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
30 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
27 mars 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Issues Letter to Stockholders
06 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03 mars 2023 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, March 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022
02 mars 2023 07h00 HE
|
Daxor Corporation
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...